These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 16026267)

  • 21. A Glycation Angle to Look into the Diabetic Vasculopathy: Cause and Cure.
    Ahmad S; Siddiqui Z; Rehman S; Khan MY; Khan H; Khanum S; Alouffi S; Saeed M
    Curr Vasc Pharmacol; 2017; 15(4):352-364. PubMed ID: 28356033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of advanced glycation end product (AGE)-induced receptor (RAGE) expression in diabetic vascular complications.
    Chawla D; Bansal S; Banerjee BD; Madhu SV; Kalra OP; Tripathi AK
    Microvasc Res; 2014 Sep; 95():1-6. PubMed ID: 24984291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incretin-Based Therapy for Prevention of Diabetic Vascular Complications.
    Mima A
    J Diabetes Res; 2016; 2016():1379274. PubMed ID: 26881236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy.
    Takeuchi M; Takino J; Yamagishi S
    Curr Drug Targets; 2010 Nov; 11(11):1468-82. PubMed ID: 20583971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NAD(P)H oxidase activation: a potential target mechanism for diabetic vascular complications, progressive beta-cell dysfunction and metabolic syndrome.
    Inoguchi T; Nawata H
    Curr Drug Targets; 2005 Jun; 6(4):495-501. PubMed ID: 16026268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alternative therapeutic principles in the prevention of microvascular and neuropathic complications.
    Gries FA
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S201-7. PubMed ID: 8529515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics.
    Schalkwijk CG; Miyata T
    Amino Acids; 2012 Apr; 42(4):1193-204. PubMed ID: 20960212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A study on serum advanced glycation end products and its association with oxidative stress and paraoxonase activity in type 2 diabetic patients with vascular complications.
    Bansal S; Chawla D; Siddarth M; Banerjee BD; Madhu SV; Tripathi AK
    Clin Biochem; 2013 Jan; 46(1-2):109-14. PubMed ID: 23103709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication.
    Yamagishi S; Nakamura K; Matsui T; Noda Y; Imaizumi T
    Curr Pharm Des; 2008; 14(5):487-95. PubMed ID: 18289075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Norman MacAlister Gregg Lecture. The pathogenesis of diabetic retinopathy.
    Larkins RG; Dunlop ME; Johnson EI
    Aust N Z J Ophthalmol; 1996 May; 24(2):97-104. PubMed ID: 9199738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of protein kinase C in diabetic microvascular complications.
    Pan D; Xu L; Guo M
    Front Endocrinol (Lausanne); 2022; 13():973058. PubMed ID: 36060954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Manifestations of cutaneous diabetic microangiopathy.
    Ngo BT; Hayes KD; DiMiao DJ; Srinivasan SK; Huerter CJ; Rendell MS
    Am J Clin Dermatol; 2005; 6(4):225-37. PubMed ID: 16060710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of protein kinase C activation in diabetic nephropathy.
    Noh H; King GL
    Kidney Int Suppl; 2007 Aug; (106):S49-53. PubMed ID: 17653211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tannins and vascular complications of Diabetes: An update.
    Laddha AP; Kulkarni YA
    Phytomedicine; 2019 Mar; 56():229-245. PubMed ID: 30668344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications.
    Wautier JL; Wautier MP; Schmidt AM; Anderson GM; Hori O; Zoukourian C; Capron L; Chappey O; Yan SD; Brett J
    Proc Natl Acad Sci U S A; 1994 Aug; 91(16):7742-6. PubMed ID: 8052654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diabetic vascular disease: it's all the RAGE.
    Hudson BI; Wendt T; Bucciarelli LG; Rong LL; Naka Y; Yan SF; Schmidt AM
    Antioxid Redox Signal; 2005; 7(11-12):1588-600. PubMed ID: 16356122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diabetic nephropathy: where hemodynamics meets metabolism.
    Forbes JM; Fukami K; Cooper ME
    Exp Clin Endocrinol Diabetes; 2007 Feb; 115(2):69-84. PubMed ID: 17318765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Therapeutic targets in diabetic vasculopathy].
    Sánchez Ferrer CF
    An R Acad Nac Med (Madr); 2003; 120(4):659-69; discussion 669-74. PubMed ID: 15147053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oxidative stress and diabetic vascular complications.
    Son SM; Whalin MK; Harrison DG; Taylor WR; Griendling KK
    Curr Diab Rep; 2004 Aug; 4(4):247-52. PubMed ID: 15265465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathological Perturbations in Diabetic Retinopathy: Hyperglycemia, AGEs, Oxidative Stress and Inflammatory Pathways.
    Sahajpal NS; Goel RK; Chaubey A; Aurora R; Jain SK
    Curr Protein Pept Sci; 2019; 20(1):92-110. PubMed ID: 30264677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.